Akèy › Kansè vejik › Indiana
Etid klinik pou Kansè vejik nan Indiana
14 etid pou Kansè vejik ap chèche patisipan nan sit nan Indiana.
Vil nan Indiana
Tèks ofisyèl etid la (Anglè)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- IU Health West Hospital, Avon
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07000084Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07566156A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Urology of Indiana - Carmel, Carmel
- Urology of Indiana, LLC (US Urology Partners), Greenwood
- First Urology, PSC, Jeffersonville
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06567743FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Indiana University (IU) Melvin and Bren Simon Cancer Center, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Urology of Indiana, Greenwood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT04752722A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- UChicago Medicine - Northwest Indiana, Crown Point
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
- Community Health Network, Inc, Indianapolis
- ak 3 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Urologic Specialists of Northwest Indiana, Merrillville
Ap rekrite
Laj 18 a 88 · Tout sèks · Mizajou Jul 2, 2026 · NCT06394869Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
- Indiana University School of Medicine, Indianapolis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 23, 2026 · NCT05982561cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881Blue Light Cystoscopy With Cysview® Registry
- Indiana University School of Medicine, Indianapolis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Dec 18, 2025 · NCT02660645Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.